Boston Scientific Stock Falls Amid Disappointing Earnings Outlook
Despite reporting better-than-expected second-quarter financial results, Boston Scientific (BSX) saw its stock fall nearly 6% in premarket trading on Wednesday. The medical device company's shares were pressured by a weaker-than-anticipated outlook for the third quarter and full year of fiscal 2026. The Massachusetts-based firm reported $5.4 billion in revenue, which exceeded expectations but failed to offset concerns over its future guidance. Investors reacted negatively as the earnings forecast fell short of analyst estimates, signaling potential challenges ahead despite strong Q2 performance.
Tickers: $BSX
Topics: Financial Performance Medical Devices Stock Market Reaction